Metsera, Inc. raised $215 million in a Series B funding round led by Wellington Management and Venrock Healthcare Capital Partners to advance its clinical-stage portfolio of peptide therapies.
Nov 13, 2024•about 1 year ago
Amount Raised
$215 Million
Round Type
series b
New YorkBiotechnologyHealth CareInvestors
Sym BiosisNewpath PartnersSoft Bank Vision Fund 2GvAlpha Wave VenturesArch Venture PartnersRa Capital ManagementDeep Track CapitalViking Global InvestorsT. Rowe Price Investment Management, Inc.T. Rowe Price Associates, Inc.Janus Henderson InvestorsFidelity Management & Research CompanyVenrock Healthcare Capital PartnersWellington Management
Description
Metsera, Inc. has successfully closed a $215 million Series B financing round to further accelerate its innovative portfolio aimed at treating obesity and metabolic diseases. The round was backed by prominent investors including Wellington Management and Venrock Healthcare Capital Partners, alongside several new and existing investors.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech